# XTL Biopharmaceuticals Ltd: Form 20-F for the period ended Dec 31, 2017

- Company: [XTL Biopharmaceuticals Ltd](/companies/xtlb.md) (CIK 1023549)
- Form: 20-F
- Filed: 2018-03-15
- Accepted by EDGAR: Mar 15, 2018, 21:12 ET
- Period: 2017-12-31
- Accession: 0001213900-18-003028
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1023549/000121390018003028/f20f2017_xtlbiopharma.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1023549/000121390018003028/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Operating income | 12 months, 2017-01-01 to 2017-12-31 | −$1.2m | ifrs-full:ProfitLossFromOperatingActivities |
| Net income | 12 months, 2017-01-01 to 2017-12-31 | −$781.0k | ifrs-full:ProfitLoss |
| Operating cash flow | 12 months, 2017-01-01 to 2017-12-31 | −$1.1m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Cash and equivalents | at 2017-12-31 | $3.3m | ifrs-full:CashAndCashEquivalents |
| Current assets | at 2017-12-31 | $6.2m | ifrs-full:CurrentAssets |
| Total assets | at 2017-12-31 | $6.6m | ifrs-full:Assets |
| Current liabilities | at 2017-12-31 | $300.0k | ifrs-full:CurrentLiabilities |
| Shareholders' equity | at 2017-12-31 | $3.6m | ifrs-full:Equity |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1023549/000121390018003028/f20f2017_xtlbiopharma.htm

Filed Mar 15, 2018.
Source: SEC EDGAR, the filing index for accession 0001213900-18-003028. Last ingested by Listed: Oct 24, 2026, 15:02 ET. No prices; not investment advice.